119 related articles for article (PubMed ID: 6702716)
1. ICRF-159 (razoxane) in patients with advanced squamous cell carcinoma of the uterine cervix. For the Gynecologic Oncology Group.
Conroy JF; Lewis GC; Blessing JA; Mangan C; Hatch K; Wilbanks G
Am J Clin Oncol; 1984 Apr; 7(2):131-3. PubMed ID: 6702716
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of cisplatin and razoxane (ICRF-159) (NSC #119875) in advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Pilot Study.
Bonomi P; Yordan E; Blessing JA
Am J Clin Oncol; 1988 Feb; 11(1):1-2. PubMed ID: 3277372
[TBL] [Abstract][Full Text] [Related]
3. ICRF-159 (razoxane) in patients with advanced nonsquamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
Homesley HD; Blessing JA; Berman M
Am J Clin Oncol; 1986 Aug; 9(4):325-6. PubMed ID: 3751970
[TBL] [Abstract][Full Text] [Related]
4. ICRF-159 (razoxane) in patients with advanced adenocarcinoma of the endometrium. A Gynecologic Oncology Group Study.
Homesley HD; Blessing JA; Conroy J; Hatch K; DiSaia PJ; Twiggs LB
Am J Clin Oncol; 1986 Feb; 9(1):15-7. PubMed ID: 3953488
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of ICRF-187 in squamous cell carcinoma of the head and neck.
Wheeler RH; Bricker LJ; Natale RB; Baker SR
Cancer Treat Rep; 1984 Feb; 68(2):427-8. PubMed ID: 6421483
[TBL] [Abstract][Full Text] [Related]
6. Phase I-II evaluation of razoxane (ICRF-159) and doxorubicin in gastrointestinal cancer. A Southeastern Cancer Study Group Trial.
DeSimone PA; Greco FA; Omura GA; Bartolucci A
Am J Clin Oncol; 1986 Jun; 9(3):185-6. PubMed ID: 3728369
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of piperazinedione (NCS 135758) in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
Thigpen JT; Blessing J; Homesley HD; Adcock LL
Am J Clin Oncol; 1983 Aug; 6(4):423-6. PubMed ID: 6688150
[TBL] [Abstract][Full Text] [Related]
8. ICRF 159 plus radiation versus radiation therapy alone in cervical carcinoma. A double-blind study.
Belloni C; Mangioni C; Bortolozzi G; Carinelli S; D'Incalci M; Maggioni A; Morasca L
Oncology; 1983; 40(3):181-5. PubMed ID: 6341912
[TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy.
Liesmann J; Belt R; Haas C; Hoogstraten B
Cancer; 1981 Apr; 47(8):1959-62. PubMed ID: 6784914
[TBL] [Abstract][Full Text] [Related]
10. ICRF-159 (razoxane) in the treatment of pediatric solid tumors: a Southwest Oncology Group study.
Dyment PG; Starling KA; Land VJ; Cangir A; Komp DM; Sexauer CL
Cancer Treat Rep; 1979 Aug; 63(8):1397-8. PubMed ID: 476712
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.
Vogl SE; Lanham R; Kaplan BH
Oncology; 1980; 37(5):314-5. PubMed ID: 7003455
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of razoxane in the management of recurrent adenocarcinoma of the ovary: a Gynecologic Oncology Group study.
Conroy JF; Blessing JA; Kessinger A; Homesley HD
Cancer Treat Rep; 1984 Feb; 68(2):439-40. PubMed ID: 6697335
[No Abstract] [Full Text] [Related]
13. Phase II study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
Thigpen JT; Ehrlich CE; Conroy J; Blessing JA
Am J Clin Oncol; 1983 Aug; 6(4):427-30. PubMed ID: 6869315
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of ICRF-187 by 48-hour continuous infusion.
Koeller JM; Earhart RH; Davis HL
Cancer Treat Rep; 1981; 65(5-6):459-63. PubMed ID: 6786740
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of razoxane (ICRF-159) in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy.
Shah MK; Engstrom PF; Catalano RB; Paul AR; Bellet RE; Creech RH
Cancer Treat Rep; 1982 Mar; 66(3):557-8. PubMed ID: 7060043
[No Abstract] [Full Text] [Related]
16. Phase II study of ICRF-159 in refractory metastatic breast cancer.
Creech RH; Engstrom PF; Harris DT; Catalano RB; Bellet RE
Cancer Treat Rep; 1979 Jan; 63(1):111-4. PubMed ID: 369681
[TBL] [Abstract][Full Text] [Related]
17. Phase III study of ICRF-159 versus 5-FU in the treatment of advanced metastatic colorectal carcinoma.
Paul AR; Catalano RB; Engstrom PF
Cancer Treat Rep; 1980; 64(10-11):1047-9. PubMed ID: 7006805
[TBL] [Abstract][Full Text] [Related]
18. Randomized clinical trial comparing two dose regimens of ICRF-159 in refractory malignant lymphomas.
O'Connell MJ; Begg CB; Silverstein MN; Glick JH; Oken MM
Cancer Treat Rep; 1980; 64(12):1355-8. PubMed ID: 7008938
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
Windschitl H; Scott M; Schutt A; McCormack G; Everson L; Cullinan S; Gerstner J; Krook J; Laurie J; Shreck R
Cancer Treat Rep; 1983 Nov; 67(11):1001-8. PubMed ID: 6640551
[TBL] [Abstract][Full Text] [Related]
20. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Thigpen T; Shingleton H; Homesley H; Lagasse L; Blessing J
Cancer; 1981 Aug; 48(4):899-903. PubMed ID: 7196794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
